Clinical trialNCT07405476RecruitingPhase 2Interventional

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

SponsorEmory UniversityEnrollment38Colon CarcinomaColorectal CarcinomaRectal CarcinomaStage I Colon Cancer AJCC v8Stage I Colorectal Cancer AJCC v8Stage I Rectal Cancer AJCC v8+6 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies how well giving zanidatamab before surgery (neoadjuvant) works in treating patients with colon and rectal cancer that is human epidermal growth factor receptor 2 positive (HER2+ve) who are planned for curative intent treatment. Zanidatamab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Olumide B. Gbolahan, MBBS, MSc
Emory University Hospital/Winship Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Emory Saint Joseph'S Hospital
Atlanta, Georgia, United States
Recruiting
Emory University Hospital
Atlanta, Georgia, United States
Olumide B. Gbolahan, MBBS, MSc
Recruiting
Emory University Hospital Midtown
Atlanta, Georgia, United States
Recruiting
Emory Decatur Hospital
Decatur, Georgia, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Zanidatamab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Apr 2026
Primary completion: 18 Dec 2028
Completion: 18 Dec 2029
Last update posted: 17 Apr 2026
Registered enrollment: 38
Registry id: NCT07405476

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.